Core Viewpoint - Robbins LLP has announced a class action lawsuit against Picard Medical, Inc. for alleged fraudulent stock promotion activities that misled investors [1] Group 1: Allegations Against Picard Medical, Inc. - The lawsuit claims that Picard Medical was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [1] - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [1] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] Group 2: Stock Price Impact - On October 24, 2025, Picard Medical's stock price fell sharply by 70%, dropping to $3.99 per share [1] - Following the initial crash, the stock price has continued to decline, reaching approximately $2.00 per share [1] Group 3: Class Action Participation - Investors who purchased Picard Medical securities between September 2, 2025, and October 31, 2025, may be eligible to participate in the class action [1] - Shareholders wishing to serve as lead plaintiff must file their papers with the court by April 3, 2026 [1] - Participation in the case is not required to be eligible for recovery, allowing investors to remain absent class members if they choose [1]

Core Viewpoint - A class action has been filed against SLM Corporation (Sallie Mae) for allegedly misleading investors about its loss mitigation and loan modification programs during a specific period in 2025 [1][2]. Group 1: Allegations and Findings - The complaint alleges that SLM failed to disclose a significant increase in early stage delinquencies, leading to an overstatement of the effectiveness of its loss mitigation and loan modification programs [2]. - A report from TD Cowen indicated that July 2025 delinquencies rose by 49 basis points month-over-month, which was worse than the expected seasonal increase of 10 basis points, driven by a 45 basis point increase in early stage delinquencies [3]. - The findings from TD Cowen contradicted SLM's previous assurances regarding delinquency rates following normal seasonal trends, resulting in a stock price drop of $2.67 per share (8.09%) to close at $30.32 on August 15, 2025 [3]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against SLM Corporation, with the option to serve as lead plaintiff or remain an absent class member [4]. - All representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - A class action has been filed against Charming Medical, Limited (NASDAQ: MCTA) for alleged fraudulent stock promotion activities that misled investors and artificially inflated the company's stock price [1][2]. Allegations - The complaint alleges that Charming Medical was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [2]. - Insiders and affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures failed to mention the false rumors and artificial trading activity that were driving the stock price [2]. Stock Price Movement - In the weeks leading up to November 12, 2025, Charming's share price increased from the initial public offering price of $4.00 to a peak of $29.36 per share, despite a lack of fundamental news justifying such a rise [3]. - Investigations revealed that the stock was subject to an illicit promotion scheme that created a buying frenzy among retail investors through sensational claims made by impersonators on social media [3]. - Trading of Charming's stock was halted by the SEC on November 12, 2025, and remains suspended due to the company's failure to provide required information to regulators [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by February 17, 2026 [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [5].

Core Viewpoint - A class action has been filed against F5, Inc. for allegedly misleading investors regarding the financial impact of a significant security breach that occurred between October 28, 2024, and October 27, 2025 [1][3]. Group 1: Class Action Details - The class period for the action is defined as October 28, 2024, to October 27, 2025 [3]. - Robbins LLP is investigating allegations that F5, Inc. misled investors about its ability to secure client data amid a significant security breach [3]. - The breach reportedly compromised the company's BIG-IP product development and engineering knowledge management platforms, including the source code [4]. Group 2: Financial Impact - Following the announcement of the security breach on October 15, 2025, F5's stock price fell from $343.17 per share on October 14, 2025, to $295.35 per share on October 16, 2025, marking a decline of approximately 13.9% [4]. - On October 27, 2025, F5 reported fourth-quarter fiscal year 2025 results that fell significantly below market growth expectations for fiscal 2026, attributing this to the security breach [5]. - The company indicated expected reductions in sales and renewals, elongated sales cycles, and increased expenses due to ongoing remediation efforts, which further impacted its stock price, dropping from $290.41 per share on October 27, 2025, to $258.76 per share on October 28, 2025, a decline of an additional 10.9% [5]. Group 3: Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers to the court by February 17, 2026, to serve as lead plaintiff [6]. - Shareholders can choose to remain absent class members without participating in the case [6].

Core Viewpoint - A class action has been filed against Klarna Group plc for allegedly misleading investors during its IPO, particularly regarding the understated risks associated with its loss reserves [1][2]. Group 1: Allegations and Misleading Information - The registration statement for Klarna's IPO is claimed to be misleading, as it did not disclose the significant risk of increased loss reserves shortly after the IPO, which was known or should have been known by the company [2]. - The complaint states that due to the omission of these material adverse facts, Klarna's stock price is now trading significantly below its IPO price [3]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against Klarna, with a deadline to submit papers to serve as lead plaintiff by February 20, 2026 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [5]. - The firm has a history of advocating for shareholder rights and aims to hold company executives accountable for their actions [5].

SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired CoreWeave, Inc. (NASDAQ: CRWV) securities between March 28, 2025 and December 15, 2025. CoreWeave purports to be an artificial intelligence (“AI”) cloud computing company and self-described “Hyperscaler”, which it defines as “a cloud provider or technology company that is capable of delivering computing infrastructure and services at massi ...

Core Viewpoint - A class action has been filed against Coupang, Inc. for failing to disclose a significant cybersecurity event that impacted the company, leading to a decline in stock price and harming investors [2]. Group 1: Allegations - Coupang allegedly had inadequate cybersecurity protocols that allowed a former employee to access sensitive customer information for nearly six months without detection [2]. - The company is accused of subjecting itself to a materially heightened risk of regulatory and legal scrutiny due to the data breach [2]. - When the breach was discovered, Coupang did not report it in a timely manner as required by U.S. Securities and Exchange Commission regulations [2]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against Coupang, with a deadline to submit papers to serve as lead plaintiff by February 17, 2026 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3]. Group 3: Company Background - Coupang is described as one of the fastest-growing technology and commerce companies globally, offering services in retail, restaurant delivery, video streaming, and fintech under various brands [1].

Core Viewpoint - A class action has been filed against Fermi Inc. (NASDAQ: FRMI) on behalf of investors who purchased shares during its IPO and within a specified period, alleging that the company misled investors about its business prospects [1][3]. Group 1: Class Action Details - The class period for the action is defined as October 25, 2025, to December 11, 2025 [3]. - Allegations include that Fermi overstated tenant demand for its Project Matador campus and failed to disclose reliance on a single tenant's funding commitment, which posed a significant risk of termination [3]. Group 2: Impact on Stock Price - On December 12, 2025, Fermi disclosed that the first tenant for Project Matador had terminated a $150 million funding agreement, leading to a stock price drop of $5.16 per share, or 33.8%, closing at $10.09 [4]. - By the time of the class action announcement, Fermi's stock had traded as low as $8.59 per share, representing a 59% decline from the IPO price of $21.00 per share [4]. Group 3: Participation in Class Action - Shareholders interested in serving as lead plaintiffs must submit their papers by March 6, 2026, but participation is not required to be eligible for recovery [5]. - All representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [6].

What can you do now? You may be eligible to participate in the class action against Blue Owl Capital Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by February 2, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, ...

Core Points - A class action has been filed on behalf of investors who purchased CoreWeave, Inc. (NASDAQ: CRWV) securities between March 28, 2025, and December 15, 2025 [1] - CoreWeave is described as an artificial intelligence cloud computing company and a "Hyperscaler," which provides computing infrastructure and services at a massive scale [1] Allegations - The complaint alleges that CoreWeave misled investors regarding its ability to meet customer demand, overstating its capabilities [2] - It is claimed that the company materially understated the risks associated with its reliance on a single third-party data center supplier, which could negatively impact revenue [2] Stock Performance - Following disclosures that revealed the truth about the company's situation, CoreWeave's stock price fell from a high of $183.58 on June 20, 2025, to $69.50 per share by December 16, 2025 [3] Class Action Participation - Shareholders interested in serving as lead plaintiff must submit their papers by March 13, 2026, and participation is not required to be eligible for recovery [4] Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5]